References
1.
Pinto
C, Lorca-Garcia C, Berenguer B, et al. Bleomycin-induced flagellate
erythema after venous malformation sclerosis-Case report and brief
review. Pediatr Dermatol, 2018. 35(1): p. e5-e8.
2.
Stefanou
A, Siderov J. Medical errors. Dosage nomenclature of bleomycin needs to
be standardised to avoid errors. BMJ, 2001. 322(7299): p. 1423-4.
3. U.S. Food and Drug Adminstration. Bleomycin sulfate instruction.
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050443
[2010, accessed 5 August 2021].
4. de
Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four
cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3-
or 5-day schedule in good-prognosis germ cell cancer: a randomized study
of the European Organization for Research and Treatment of Cancer
Genitourinary Tract Cancer Cooperative Group and the Medical Research
Council. J Clin Oncol, 2001. 19(6): p. 1629-40.
5.
Loehrer
PS, Johnson D, Elson P, et al. Importance of bleomycin in
favorable-prognosis disseminated germ cell tumors: an Eastern
Cooperative Oncology Group trial. J Clin Oncol, 1995. 13(2): p. 470-6.
6.
Culine
S, Kramar A, Theodore C, et al. Randomized trial comparing
bleomycin/etoposide/cisplatin with alternating
cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin
regimens of chemotherapy for patients with intermediate- and poor-risk
metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the
French Federation of Cancer Centers Trial T93MP. J Clin Oncol, 2008.
26(3): p. 421-7.
7.
Azambuja
E, Fleck JF, Batista RG, et al. Bleomycin lung toxicity: who are the
patients with increased risk? Pulm Pharmacol Ther, 2005. 18(5): p.
363-6.
8.
Tobwala
S, Fan W, Stoeger T, et al. N-acetylcysteine amide, a thiol antioxidant,
prevents bleomycin-induced toxicity in human alveolar basal epithelial
cells (A549). Free Radic Res, 2013. 47(9): p. 740-9.
9.
Shahbaz
M, Kamran SH, Anwar R. Amelioration of Bleomycin and
Methotrexate-Induced Pulmonary Toxicity by Serratiopeptidase and
Fisetin. Nutr Cancer, 2020: p. 1-10.
10.
Sakamoto
K, Ito S, Hashimoto N, et al. Pirfenidone as salvage treatment for
refractory bleomycin-induced lung injury: a case report of seminoma. BMC
Cancer, 2017. 17(1): p. 526.
11.
White
DA, Stover DE. Severe bleomycin-induced pneumonitis. Clinical features
and response to corticosteroids. Chest, 1984. 86(5): p. 723-8.
12.
Radford
J, Illidge T, Counsell N, et al. Results of a trial of PET-directed
therapy for early-stage Hodgkin’s lymphoma. N Engl J Med, 2015. 372(17):
p. 1598-607.
13.
Straus
DJ, Jung SH, Pitcher B, et al. CALGB 50604: risk-adapted treatment of
nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood, 2018.
132(10): p. 1013-1021.
14.
Johnson
P, Federico M, Kirkwood A, et al. Adapted Treatment Guided by Interim
PET-CT Scan in Advanced Hodgkin’s Lymphoma. N Engl J Med, 2016. 374(25):
p. 2419-29.
Figure 1 Schematic historical and current information from the
episode of care